VivoSeq
Other

GIST

3

Pipeline Programs↗

15

Active Trials↗

22

Companies Involved↗

GIST is an early-stage landscape with 3 programs across 22 companies. The most active players are Novartis, Deciphera Pharmaceuticals, LLC, Pfizer. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

ApprovedD

Deciphera Pharmaceuticals, LLC

2 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical2

Inlexisertib

Deciphera Pharmaceuticals, LLC

Ripretinib

Deciphera Pharmaceuticals, LLC

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Imatinib

Novartis

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSProtein / enzyme133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

72

clinical trials

Completed33 · 46%
Unknown status16 · 22%
Recruiting9 · 13%
Terminated6 · 8%
Active, not recruiting4 · 6%
Not yet recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

72 trials

START-Register: Survey on Anticoagulated Patients Register
Recruiting·GGUALTIERO PALARETI·N/A·NCT02219984·15,410 enrolled
Cognitive Neurology Unit Clinical Registry
Recruiting·—·N/A·NCT05925621·500 enrolled
Blue Light Cystoscopy With Cysview® Registry
Recruiting·PPhotocure·N/A·NCT02660645·4,400 enrolled
University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting·—·N/A·NCT04480918·1,000 enrolled
Registry of Patients Having Received oNKord®
Recruiting·GGlycostem Therapeutics BV·N/A·NCT05290662·50 enrolled
Imatinib TDM in GIST
Recruiting·—·Phase 2·NCT05493215·28 enrolled
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Recruiting·AAmryt Pharma·N/A·NCT02135705·300 enrolled
Life Raft Group GIST Registry Protocol
Recruiting·TThe Life Raft Group·N/A·NCT07697248·5,000 enrolled
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Recruiting·DDeciphera Pharmaceuticals, LLC·Preclinical·NCT05957367·94 enrolled
Swedish Ibrance Registries Insights (SIRI)
Active, not recruiting·Pfizer logoPfizer·N/A·NCT04654208·1,500 enrolled
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Active, not recruiting·United Therapeutics logoUnited Therapeutics·N/A·NCT03045029·300 enrolled
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Active, not recruiting·Taiho Pharmaceutical Co., Ltd. logoTaiho Pharmaceutical Co., Ltd.·Phase 1·NCT05245968·78 enrolled
The REPLACE Registry for Cholbam® (Cholic Acid)
Active, not recruiting·MMirum Pharmaceuticals, Inc.·N/A·NCT03115086·55 enrolled
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
Not yet recruiting·CCaja Costarricense de Seguro Social·N/A·NCT07448402·50 enrolled
PH 2 Pemigatinib in SDH-deficient GIST
Not yet recruiting·—·Phase 2·NCT07434843·24 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)